4-isopentylpyridine | 4810-78-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-isopentylpyridine
• 英文别名: 4-(3-methylbutyl)pyridine
• CAS: 4810-78-0
• 化学式: C₁₀H₁₅N
• 分子量: 149.236
• InChiKey: BBACXGWZBLUKNG-UHFFFAOYSA-N

物化性质

• 沸点：
  225-227 °C
• 密度：
  0.9040 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-isopentylpyridine 在 氯代十四烷 作用下， 生成 4-isopentyl-1-tetradecyl-pyridinium; chloride
  参考文献：
  名称：

  Quaternary Ammonium Salts as Germicides. IV. Quaternary Ammonium Salts Derived from Substituted Pyridines

  摘要：

  DOI：

  10.1021/ja01152a119
• 作为产物：
  描述：

  溴代异丁烷 在 正丁基锂 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以98%的产率得到4-isopentylpyridine
  参考文献：
  名称：

  WO2007/128059

  摘要：

  公开号：

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS
  申请人：Wang Tao

  公开号：US20070249579A1

  公开（公告）日：2007-10-25

  This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.

  本公开提供具有药物和生物影响特性的化合物，它们的药物组合物和使用方法。具体而言，该公开涉及具有独特抗病毒活性的二酮哌嗪和哌啶衍生物。更具体地说，本公开涉及用于治疗艾滋病毒和艾滋病的化合物。
• Azatricycles from substituted pyridines. Synthesis and rearrangement of N-ethoxycarbonyl-2-azatricyclo[4.3.1.03,7]dec-8-enes.
  作者：Grant R. Krow、Yoon B. Lee、Ramesh Raghavachari、Steven W. Szczepanski、Peter V. Alston

  DOI：10.1016/s0040-4020(01)82393-0

  日期：1991.9

  The scope and relative rates of intramolecular cycloaddition reactions of methyl-substituted 2-[3-butenyl]-1,2-dihydropyridines have been studied. Cycloadducts can be rearranged to upon reaction with bromine, except when olefinic methyl groups are present.

  已经研究了甲基取代的2- [3-丁烯基] -1，2-二氢吡啶类分子内环加成反应的范围和相对速率。Cycloadducts可以重新排列，以在与溴反应，除了当烯属甲基的基团存在。
• Anti-Viral Compounds
  申请人：DeGoey David A.

  公开号：US20100168138A1

  公开（公告）日：2010-07-01

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  描述了一种有效抑制丙型肝炎病毒（“HCV”）复制的化合物。本发明还涉及制备这种化合物的方法、包含这种化合物的组合物，以及使用这种化合物治疗HCV感染的方法。
• [EN] SUBSTITUTED AMIDE BETA SECRETASE INHIBITORS<br/>[FR] INHIBITEURS D'AMIDE BETA SECRETASE SUBSTITUES
  申请人：SCHERING CORP

  公开号：WO2006014762A1

  公开（公告）日：2006-02-09

  Disclosed are novel compounds of the formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4 and X are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are methods of treating a cognitive or neurodegenerative disease comprising administering to a patient I need of such treatment a combination of at least one compound of formula (I) and at least one compound selected from the group consisting of β-secretase inhibitors other than those of formula (I), HMG-CoA reductase inhibitors, gamma-secretase inhibitors, non-steroidal anti-inflammatory agents, N-methyl-D-aspartate receptor antagonists, cholinesterase inhibitors and anti-amyloid antibodies.

  揭示了公式（I）的新化合物或其药学上可接受的盐或溶剂，其中R1、R2、R3、R4和X如规范中所定义。还揭示了包括公式（I）化合物的药物组合物。还揭示了治疗认知或神经退行性疾病如阿尔茨海默病的方法。还揭示了治疗认知或神经退行性疾病的方法，包括向需要此类治疗的患者施用公式（I）化合物中至少一种与β-分泌酶抑制剂、HMG-CoA还原酶抑制剂、γ-分泌酶抑制剂、非甾体抗炎药、N-甲基-D-天冬氨酸受体拮抗剂、胆碱酯酶抑制剂和抗淀粉样抗体等组中除公式（I）之外的至少一种化合物的组合物。